cbdMD CEO receives 445,000 restricted shares under 2025 equity plan
cbdMD, Inc. reported an insider equity transaction for its CEO and CFO, who is also a director, on a Form 4.
Rhea-AI Filing Summary
cbdMD, Inc. reported an insider equity transaction for its CEO and CFO, who is also a director, on a Form 4. On 11/28/2025, the executive acquired 445,000 shares of common stock as restricted stock. After this grant, the executive beneficially owns 513,722 common shares in total.
The restricted shares were granted under cbdMD’s 2025 Equity Compensation Plan, and the filing notes that the vesting and issuance of these shares are subject to shareholder approval. The company also explains that the current beneficial ownership amount does not reconcile to the prior report because of a scrivener’s error.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 445,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. The shares of restricted stock were granted pursuant to the Issuer's 2025 Equity Compensation Plan. The vesting and issuance of the shares is subject to shareholder approval.
- F2. The amount beneficially owned will not reconcile to the prior Form 4 due to a scriveners error.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did cbdMD (YCBD) report in this Form 4?
Who is the reporting person in this cbdMD (YCBD) Form 4 and what is their role?
Why does the cbdMD (YCBD) beneficial ownership amount differ from a prior report?
AI-generated analysis. How Rhea-AI works. Not financial advice.